AW
A stranger
LIVERHOPE: SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS
ALFASIGMA SPA
participó en un
H2020:
H2020-SC1-2016-2017
Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact...
2016-12-09 - 2023-02-28 | financed
2016-12-09 - 2023-02-28 | financed
* No data from the current company are not available.